Clinical trials: Neoplasia Prostate
Prostate Adenocarcinoma, Radiotherapy; Complications
Twice High Dose External Beam Radiotherapy by Image-guided Tomotherapy for Organ-confined Prostate Cancer Treatment Emulating High Dose Radiation (HDR) Brachytherapy
Feasibility trial of twice high dose radiotherapy using Tomotherapy in patients with organ confined Prostate Cancer histologically proven.
- Conditions
- Prostate Adenocarcinoma, Radiotherapy; Complications, Tomotherapy
- Trial name
- THRIP (NCT03553212)
- Testing
- tomotherapy
- Where
- Italy
- Volunteers
- 2 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Prostatic Neoplasm
Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial
The purpose of this study is to determine the most appropriate radiation implant dose for palladium-103 monotherapy. Radiation dose is related to potential cure.
- Trial name
- NCT00247312
- Testing
- Pd-103
- Where
- 2 sites in United States
- Volunteers
- 319 people, healthy volunteers welcome
- Sponsor
- Schiffler Cancer Center
Prostate Cancer
Hypofractionated Expedited Radiotherapy for Men With localisEd proState Cancer
The purpose of this research is to investigate whether stereotactic body radiotherapy (SBRT), precise X-ray treatment, is best given in five treatments (also called fractions) over 10 days or in two treatments over 8 days.
- Trial name
- HERMES (NCT04595019)
- Testing
- SBRT
- Where
- United Kingdom
- Volunteers
- 46 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Adenocarcinoma of the Prostate
Radiation and Androgen Ablation for Prostate Cancer
A study to see how effective and tolerable radiation therapy along with androgen deprivation therapy is in treating prostate cancer.
- Trial name
- NCT01517451
- Testing
- Radiation Therapy, Androgen Deprivation Therapy (ADT)
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Castration Resistant Prostate Cancer
IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer
Dose escalation study to evaluate the safety, tolerability and anti-tumor activity of single agent IMU-935 in patients with progressive, metastatic castration resistant prostate cancer (mCRPC).
- Trial name
- NCT05124795
- Testing
- IMU-935
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Immunic AG
Prostate Cancer
Androcur Non-interventional Study Among Patients With Carcinoma of the Prostate
Cyproterone acetate (CPA) is a steroidal antiandrogen which has affinity with progesterone and with glucocorticoid receptors. Cyproterone acetate is long-term proven effective treatment of inoperable carcinoma of the prostate.
- Trial name
- ANES (NCT00919022)
- Testing
- Cyproterone Acetate (Androcur, BAY94-8367)
- Where
- Czechia
- Volunteers
- 194 people
- Sponsor
- Bayer
Locally Advanced Prostate Cancer
TNFerade Biologic to Treat Locally Advanced Prostate Cancer
While radiation therapy with androgen ablation (hormone reduction) is the standard method of treating locally advanced prostate cancer.
- Trial name
- NCT01048151
- Testing
- TNFerade™ Biologic
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- GenVec
Malignant Neoplasm of Prostate
Exercise Therapy and Radiation Therapy (EXERT) for Metastatic Prostate Cancer
This study is being done to determine if patients receiving personalized exercise therapy (versus those who do not receive personalized exercise therapy) have improved quality of life and physical functioning after completing…
- Trial name
- NCT04556045
- Testing
- Exercise therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer, Prostate Cancer
Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease
The purpose of this study is to determine the effect of AZD0530 on subjects with breast cancer or prostate cancer with metastatic bone disease in comparison to zoledronic acid.
- Conditions
- Breast Cancer, Prostate Cancer, Bone Neoplasms
- Trial name
- NCT00558272
- Testing
- AZD0530, Zoledronic Acid
- Where
- 28 sites in United States, Canada and 6 more
- Volunteers
- 139 people
- Sponsor
- AstraZeneca
Melanoma, Prostate Adenocarcinoma
Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors
The goal of this clinical research study is to evaluate the safety of PEG-BCT- 100 given as an infusion to treat patients who bear advanced solid tumors that are dependent on arginine (melanoma, renal cell carcinoma, prostate…
- Trial name
- NCT02285101
- Testing
- PEG-BCT-100
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Bio-Cancer Treatment International Limited
Metastatic Castration-sensitive Prostate Cancer
Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan
To evaluate changes in genomic alterations for 73 PC driver genes during apalutamide treatment
- Trial name
- CUARTET (NCT04601441)
- Testing
- Apalutamide
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Kindai University
Prostate Cancer
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
The purpose of this study is to test if treatment with medications that reduce the male hormone level in the participant's body for a few months before surgery can shrink prostate cancer as much as possible, which might reduce…
- Trial name
- NCT03436654
- Testing
- Apalutamide, Abiraterone Acetate, Prednisone
- Where
- 11 sites in United States
- Volunteers
- 102 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer, Ovarian Cancer
Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)
This study investigates the safety and efficacy of Acetyl-L-Carnitine and compares it to the safety and efficacy of a placebo (inactive) tablet in the prevention of Sagopilone-induced peripheral neuropathy.
- Trial name
- NCT00751205
- Testing
- Sagopilone 16 mg/m^2 i.v., Acetyl-L-Carnitine (ALC) 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid
- Where
- 22 sites in Belgium, France and 4 more
- Volunteers
- 150 people
- Sponsor
- Bayer
Breast Cancer, Cognitive/Functional Effects
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
RATIONALE: Stereotactic radiation therapy can send x-rays directly to the tumor and cause less damage to normal tissue. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Conditions
- Breast Cancer, Cognitive/Functional Effects, Lung Cancer, Metastatic Cancer
- Trial name
- NCT00377156
- Testing
- radiation therapy, stereotactic radiosurgery
- Where
- 64 sites in United States, Canada
- Volunteers
- 213 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer
The purpose of this study is to compare the effects (good and bad) on patients with prostate cancer by comparing the standard dose of radiation therapy (44 treatments over 8½-9 weeks) with a higher daily dose of radiation (5…
- Trial name
- NCT01230866
- Testing
- Proton Radiation Hypofractionation, Proton Radiation Standard Fractionation
- Where
- 5 sites in United States
- Volunteers
- 150 people
- Sponsor
- Proton Collaborative Group
Prostatic Neoplasm
Active Surveillance or Radical Treatment for Newly Diagnosed Patients With a Localized, Low Risk, Prostate Cancer START
The purpose of the START project is to evaluate the acceptability, the safety and the cost-effectiveness of a population based program of active surveillance for patients newly diagnosed with a localized, low risk, prostate…
- Trial name
- START (NCT03348722)
- Testing
- Active surveillance, Radical prostatectomy, Radiotherapy
- Where
- Italy
- Volunteers
- 850 people
- Sponsor
- Rete Oncologica Piemonte, Valle d'Aosta
Metastatic Castration-Resistant Prostate Cancer
Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients
This is a phase II study which will test the study drug MLN0128 in patients with castration resistant prostate cancer who have received chemotherapy in the past.
- Trial name
- NCT02091531
- Testing
- MLN0128
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Prostatic Adenocarcinoma
Phase II Study of Docetaxel Before Degarelix in Patients With Newly Diagnosed Metastatic Prostate Cancer.
The purpose of this study is to look at patient outcomes when docetaxel is started prior to ADT with degarelix.
- Trial name
- NCT03069937
- Testing
- Docetaxel, Degarelix
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Medical University of South Carolina
Prostate Cancer
Multi-Center Randomized Clinical Trial Irreversible Electroporation for the Ablation of Localized Prostate Cancer
Multi-centre Randomized Clinical Trial: 106 patients with confirmed unilateral high-volume low risk (Gleason score 3 + 3) or intermediate risk prostate cancer (Gleason score 3 + 4) will undergo an IRE treatment.
- Trial name
- NCT01835977
- Testing
- Irreversible Electroporation (Nanoknife)
- Volunteers
- 106 people
- Sponsor
- Clinical Research Office of the Endourological Society
Prostate Cancer
Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study)
Multiparametric MRI (mpMRI) of the prostate is an important tool for diagnosis of clinically significant prostate cancer (csPCa) in men with an elevated serum prostate specific antigen, which can decrease the rate of unnecessary…
- Trial name
- NCT05043012
- Testing
- flexible AIR coil, endorectal coi
- Where
- United States
- Volunteers
- 258 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.